Chinese Medical Journal (Mar 2023)

Effects of coronavirus disease 2019 vaccination on seizures in patients with epilepsy

  • Xiqin Fang,
  • Shan Qiao,
  • Ranran Zhang,
  • Tingting Yang,
  • Zhihao Wang,
  • Qingxia Kong,
  • Meihua Sun,
  • Jianhong Geng,
  • Chunyan Fang,
  • Yanxiu Chen,
  • Yanping Sun,
  • Dongmei Zhang,
  • Lixing Qu,
  • Wei Shang,
  • Jianguo Wang,
  • Xuewu Liu,
  • Xiangxiang Pan,
  • Peifang Wei

DOI
https://doi.org/10.1097/CM9.0000000000002558
Journal volume & issue
Vol. 136, no. 5
pp. 571 – 577

Abstract

Read online

Abstract. Background:. Given that seizures may be triggered by vaccination, this study aimed to evaluate the risk and correlative factors of seizures in patients with epilepsy (PWE) after being vaccinated against coronavirus disease 2019 (COVID-19). Methods:. This study retrospectively enrolled PWE who were vaccinated against COVID-19 in the epilepsy centers of 11 hospitals in China. We divided the PWE into two groups as follows: (1) patients who developed seizures within 14 days of vaccination were assigned to the SAV (with seizures after vaccination) group; (2) patients who were seizure-free within 14 days of vaccination were assigned to the SFAV (seizure-free after vaccination) group. To identify potential risk factors for seizure reccurence, the binary logistic regression analysis was performed. Besides, 67 PWE who had not been vaccinated were also included for elucidating the effects of vaccination on seizures recurrence, and binary logistic regression analysis was performed to determine whether vaccination would affect the recurrence rate of PWE who had drug reduction or withdrawal. Results:. The study included a total of 407 patients; of which, 48 (11.8%) developed seizures within 14 days after vaccination (SAV group), whereas 359 (88.2%) remained seizure-free (SFAV group). The binary logistic regression analysis revealed that duration of seizure freedom (P 3 months before vaccination should be vaccinated. Whether the remaining PWE should be vaccinated depends on the local prevalence of COVID-19. Finally, PWE should avoid discontinuing ASMs or reducing their dosage during the peri-vaccination period.